青年科学基金进展顺利，研究证实，低分子量肝素LMWH通过同时下调及结合肿瘤及内皮细胞上vimentin发挥其抗肿瘤生长和转移作用。发表高水平药理学SCI论文。已有研究发现，vimentin表达的下调能够增加非小细胞肺癌NSCLC对表皮生长因子靶向治疗药物吉非替尼（Gefitinib）的敏感性。我们知道，近年来吉非替尼用于NSCLC的治疗取得突破性进展，然而其耐药现象严重。目前无有效治疗措施。我们前期研究结果显示，LMWH与吉非替尼合用能有效的抑制吉非替尼耐药NSCLC细胞系A549增殖和其中vimentin表达。本申请项目拟从vimentin角度探析LMWH与吉非替尼联合用药对吉非替尼耐药的NSCLC的治疗作用。为临床NSCLC的吉非替尼耐药后的临床治疗提供合理的依据和LMWH的抗肿瘤辅助治疗作用提出新的应用前景。

My Youth Science Foundation is progressing smoothly; the study confirmed low molecular weight heparin (LMWH) has anti-tumor and metastasis effects by regulating and combining with vimentin in tumor cells and endothelial cells. Related SCI papers have been published. Some other studies have shown that down-regulation of vimentin expression increase the sensitivity of non-smallcell lung cancer (NSCLC) to gefitinib, an epidermal growth factor targeted therapy drug. As we have known, in recent years the clinic use of gefitinib on patients with NSCLC take a breakthrough for NSCLC treatment. However, drug resistance to gefitinib is serious. There are currently no effective treatment measures. Our preliminary study results showed that LMWH with gefitinib in combination can effectively inhibit the proliferation of gefitinib-resistant NSCLC cell lines A549 and down-regulate the expression of vimentin. Present project are intended to prove LMWH sensitizes NSCLC to gefinitib via down-regulation of vimentin. This research will provide a reasonable basis for the therapy of gefitinib-resistance and propose a new application prospect for LMWH.